Related Experiment Video
Updated: Aug 15, 2026

09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis
Sin C Lau1, Daniela D Rosa, Gordon Jayson
1Cancer Research UK, Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.
Abstract:
sanofi-aventis (formerly Aventis) and Regeneron are developing systemic VEGF Trap, a soluble decoy receptor comprising portions of VEGF receptors 1 and 2, for the potential intravenous/subcutaneous treatment of cancer.

